TS-23 is under clinical development by Translational Sciences and currently in Phase I for Thrombosis. According to GlobalData, Phase I drugs for Thrombosis have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TS-23’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DS-9231 (TS23) is under development for thrombosis, acute pulmonary embolism, myocardial infarction and ischemic stroke. It is a blood clot dissolving agent. The drug candidate is an alpha 2 plasmin inhibitor. It is administered through intravenous route.
For a complete picture of TS-23’s drug-specific PTSR and LoA scores, buy the report here.